Treating glucosphingolipid disorders by chemotherapy: Use of approved drugs and over-the-counter remedies

Journal of Inherited Metabolic Disease

Volumn 23, Issue 8, 2000, Pages 767-777

  Radin, N S ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; ACARBOSE; ALGLUCERASE; ALPHA GALACTOSIDASE; ANTIOXIDANT; BETA GALACTOSIDASE; CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; CYCLOSERINE; DOXORUBICIN; FENRETINIDE; GLOBOTRIAOSYLCERAMIDE; GLUCOCORTICOID; GLUCOSE; GLUCOSIDASE; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; HEMOGLOBIN; HYDROLASE; LACTOSYLCERAMIDE; MIFEPRISTONE; MIGLUSTAT; NON PRESCRIPTION DRUG; RETINOIC ACID DERIVATIVE; RETINOL; TAMOXIFEN; UNINDEXED DRUG; URIDINE DIPHOSPHATE GLUCOSE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DRUG APPROVAL; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; EVIDENCE BASED MEDICINE; FABRY DISEASE; FUCOSIDOSIS; GAUCHER DISEASE; GM1 GANGLIOSIDOSIS; HUMAN; LIPID STORAGE; LIPIDOSIS; LOW FAT DIET; MOUSE; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; SANDHOFF DISEASE; SUBSTITUTION THERAPY; TAY SACHS DISEASE; TREATMENT PLANNING;

ANIMALS; CERAMIDES; DRUGS, NON-PRESCRIPTION; HORMONES; HUMANS; PRESCRIPTIONS, DRUG; SPHINGOLIPIDOSES; SPHINGOLIPIDS;

EID: 0034515314     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026796200760     Document Type: Article

References (40)

1. Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase
2. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation
3. N-Butyldeoxygalactonojirimycin: A more selective inhibitor of GSL biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo
4. L-Carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: Role of inhibition of ceramide generation
5. Tamoxifen retards glycosphingolipid metabolism in human cancer cells
6. Studies of the action of ceramide-like substances (D- and L-threo-PDMP) on sphingolipid glycosyltransferases and purified lactosylceramide synthase
7. Dexamethasone-induced thymocyte apoptosis: Apoptotic signal involves the sequential activation of phosphoinositide-specific phospholipase C, acidic sphingomyelinase, and caspases
8. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
9. Normalization of liver glucosylceramide levels in the "Gaucher" Mouse by phosphatidylserine injection
10. Purification and characterization of a membrane-bound nonlysosomal ceramidase from rat brain
11. Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice
12. Glycosphingolipid synthesis and proliferation in a renal cell line grown in high glucose
13. A ceramide analog (PDMP) inhibits glycolipid synthesis in fish embryos
14. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation
15. Effects of naturally occurring sugars on Ehrlich ascites tumor growth in mice
16. Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes
17. Changes in liver lipids after administration of 2-decanoylamino-3-morpholinopropiophenone and chlorpromazine
18. Antitumor activity in mice of an inhibitor of glycosphingolipid biosynthesis
19. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin
20. Galactosylceramide- and lactosylceramide-loading studies in cultured fibroblasts from normal individuals and patients with globoid cell leukodystrophy (Krabbe's disease) and GM1-gangliosidosis
21. Mifepristone-Auxiliary therapeutic use in cancer and related disorders
22. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells
23. Improved inhibitors of glucosylceramide synthase
24. Dexamethasone modulates rat renal brush border membrane phosphate transporter mRNA and protein abundance and GSL composition
25. L-Cycloserine slows the clinical and pathological course in mice with globoid cell leukodystrophy (twitcher mice)
26. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione
27. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death
28. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics
29. The effects of L-arginine on crypt cell hyperproliferation in colorectal cancer
30. Lamellar granule biogenesis: A role for ceramide glucosyltransferase, lysosomal enzyme transport, and the Golgi
31. Increase of ceramide and induction of mixed apoptosis necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines
32. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases
33. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin
34. Treatment of Gaucher's disease with an enzyme inhibitor
35. Chemotherapy by slowing glucosphingolipid synthesis
36. Control of kidney size by sex hormones; possible involvement of glucosylceramide
37. Rapid kidney changes resulting from glycosphingolipid depletion by treatment with a glucosyltransferase inhibitor
38. Pleiotropic effects of growth hormone and insulin-like growth factor IGF-1 on biological aging: Inferences from moderate caloric-restricted animals
39. Perturbations in the control of cellular arachidonic acid levels block cell growth and induce apoptosis in HL-60 cells
40. A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus